Sign inJoin waitlistJoin the waitlist

Padmanee Sharma

Co-Director of Parker Institute for Cancer Immunotherapy · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Parker Institute for Cancer Immunotherapy Center · University of Texas M D Anderson Cancer Center
Present
James P. Allison Institute Center · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Memorial Sloan Kettering Cancer Center
2000–2004
Internal Medicine
New York Presbyterian Hospital
1998–2000
Pennsylvania State University
Penn State College of Medicine
1994–1998

Research

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2015 · 4,745 citations
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Review · Cell · 2017 · First of 4 authors · Corresponding · 4,507 citations
The future of immune checkpoint therapy
Review · Science · 2015 · First of 2 authors · Corresponding · 3,867 citations

James Allison
83 papers
Jennifer Wargo
37 papers
Jianjun Gao
29 papers · 3 as a fellow
Sangeeta Goswami
28 papers · 1 as a fellow
Sumit Subudhi
27 papers
Patrick Hwu
23 papers
AD
Adi Diab
21 papers · 1 as a fellow
Michael Davies
18 papers
Michael Tetzlaff
18 papers
Alexander Lazar
17 papers · 6 as a fellow
Nizar Tannir
15 papers
Rodabe Amaria
14 papers

Grants

Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
National Cancer Institute · R01
PI · $2.5M · University of Tx Md Anderson Can Ctr
2023–2028
Targeting the ICOS/ICOSL Pathway to Improve Anti-Tumor Immune Responses
National Cancer Institute · R01
Contact PI · $1.6M · University of Tx Md Anderson Can Ctr
2012–2016

Clinical trials

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2023–2028
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
Principal investigator · Completed · Early phase 1
M.D. Anderson Cancer Center
2016–2022
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
Principal investigator · Active not recruiting · Early phase 1
M.D. Anderson Cancer Center
2014–2026
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
Principal investigator · Completed · Early phase 1
M.D. Anderson Cancer Center
2014–2019